Technology overview and drug delivery application of proniosome

References

• Song S, Tian B, Chen F, et al. Potentials of proniosomes for improving the oral bioavailability of poorly water-soluble drugs. Drug Dev Ind Pharm 2015;41:51–62
   PubMed Web of Science ®Google Scholar
• Ahmad MZ, Akhter S, Mohsin N, et al. Transformation of curcumin from food additive to multifunctional medicine: nanotechnology bridging the gap. Curr Drug Discov Technol 2014;11:197–213
   PubMedGoogle Scholar
• Ahmad MZ, Akhter S, Rahman Z, et al. Nanometric gold in cancer nanotechnology: current status and future prospect. J Pharm Pharmacol 2013;65:634–651
   PubMed Web of Science ®Google Scholar
• Ahmad MZ, Alkahtani SA, Akhter S, et al. Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art. J Drug Target 2015 . [Epub ahead of print]. DOI: 10.3109/1061186X.2015.1055570
   Web of Science ®Google Scholar
• Hu C, Rhodes DG. Proniosomes: a novel drug carrier preparation. Int J Pharm 1999;185:23–35
   PubMed Web of Science ®Google Scholar
• Hu C, Rhodes DG. Erratum to ‘proniosomes: a novel drug carrier preparation’. Int J Pharm 2000;206:109–122
   PubMed Web of Science ®Google Scholar
• Couvreur P, Fattal E, Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. Pharm Res 1991;8:1079–1086
   PubMed Web of Science ®Google Scholar
• Gregoriadis G, Florence A, Harish MP. (eds.). Liposomes in drug delivery. Langhorne (PA): Harwood Academic Publishers; 1993
   Google Scholar
• Kim S. Liposomes as carriers of cancer chemotherapy. Current status and future prospects. Drugs 1993;46:618–638
   PubMed Web of Science ®Google Scholar
• Booser DJ, Hortobagyi GN. Anthracycline antibiotics in cancer therapy. Focus on drug resistance. Drugs 1994;47:223–258
   PubMed Web of Science ®Google Scholar
• Barber R, Shek P. Liposomes as a topical ocular drug delivery system. In: Rolland A, ed. Pharmaceutical particulate carriers. New York: Marcel Dekker; 1993:1–20
   Google Scholar
• Hunt C, Tsang S. αTocopherol retards auto-oxidation and prolongs the shelf-life of liposomes. Int J Pharm 1981;8:101–110
   Web of Science ®Google Scholar
• Frfkjaer S, Hjorth E, Wfrtis O. Stability testing of liposomes during storage. In: Gregoriadis G, ed. Liposome technology, vol. 1. Boca Raton (FL): CRC Press; 1984:235–245
   Google Scholar
• Yasam VR, Jakki SL, Natarajan J, et al. A review on novel vesicular drug delivery: proniosomes. Drug Deliv 2014;21:243–249
   PubMed Web of Science ®Google Scholar
• Wong M, Thompson TE. Aggregation of dipalmitoylphosphatidylcholine vesicles. Biochemistry 1982;21:4133–4139
   PubMed Web of Science ®Google Scholar
• El-Laithy HM, Shoukry O, Mahran LG. Novel sugar esters proniosomes for transdermal delivery of vinpocetine: preclinical and clinical studies. Eur J Pharm Biopharm 2011;77:43–55
   PubMed Web of Science ®Google Scholar
• Elhissi A, Hidayat K, Phoenix DA, et al. Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm 2013;444:193–199
   PubMed Web of Science ®Google Scholar
• Vora B, Khopade AJ, Jain K. Proniosome based transdermal delivery of levonorgestrel for effective contraception. J Control Release 1998;54:149–165
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Sammour OA, Hammad MA, et al. In vitro evaluation of proniosomes as a drug carrier for flurbiprofen. AAPS PharmSciTech 2008;9:782–790
   PubMed Web of Science ®Google Scholar
• Shehata TM, Abdallah MH, Ibrahim MM. Proniosomal oral tablets for controlled delivery and enhanced pharmacokinetic properties of acemetacin. AAPS PharmSciTech 2015;16:375–383
   PubMed Web of Science ®Google Scholar
• Mokhtar M, Sammour OA, Hammad MA, et al. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm 2008;361:104–111
   PubMed Web of Science ®Google Scholar
• Zidan AS, Mokhtar M. Multivariate optimization of formulation variables influencing flurbiprofen proniosomes characteristics. J Pharm Sci 2011;100:2212–2221
   PubMed Web of Science ®Google Scholar
• Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box–Behnken design. AAPS PharmSciTech 2007;8:E86
   PubMed Web of Science ®Google Scholar
• Veerareddy PR, Bobbala SK. Enhanced oral bioavailability of isradipine via proniosomal systems. Drug Dev Ind Pharm 2013;39:909–917
   PubMed Web of Science ®Google Scholar
• Akhilesh D, Prabhu P, Faishal G. Comparative study of carriers used in proniosomes. Int J Pharm Chem Sci 2012;4:307–314
   Google Scholar
• Yadav K, Yadav D, Saroha K, et al. Proniosomal gel: a provisicular approach for transdermal drug delivery. Der Pharm Lett 2010;2:189–198
   Google Scholar
• Abd-Elbary A, El-laithy HM, Tadros MI. Sucrose stearate-based proniosome-derived niosomes for the nebulisable delivery of cromolyn sodium. Int J Pharm 2008;357:189–198
   PubMed Web of Science ®Google Scholar
• Fang JY, Yu SY, Wu PC, et al. In-vitro skin permeation of estradiol from various proniosome formulations. Int J Pharm 2001;215:91–99
   PubMed Web of Science ®Google Scholar
• Gupta A, Prajapati S, Balamurugan M, et al. Design and development of a proniosomal transdermal drug delivery system for captopril. Trop J Pharm Res 2007;6:687–693
   Web of Science ®Google Scholar
• Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes. AAPS PharmSci 2001;3:E1
   PubMed Web of Science ®Google Scholar
• Blazek-Welsh AI, Rhodes DG. SEM imaging predicts quality of niosomes from maltodextrin-based proniosomes. Pharm Res 2001;18:656–661
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Sternberg B, Florence AT. Preparation and properties of vesicles (niosomes) of sorbitan monoesters (Span 20, 40, 60 and 80) and a sorbitan triester (Span 85). Int J Pharm 1994;105:1–6
   Web of Science ®Google Scholar
• Alsarra IA, Bosela AA, Ahmed SM, et al. Proniosomes as a drug carrier for transdermal delivery of ketorolac. Eur J Pharm Biopharm 2005;59:485–490
   PubMed Web of Science ®Google Scholar
• Alsarra IA. Evaluation of proniosomes as an alternative strategy to optimize piroxicam transdermal delivery. J Microencapsul 2009;26:272–278
   PubMed Web of Science ®Google Scholar
• Lieberman H, Lachman L, Schwartz J. Pharmaceutical dosage forms: tablets, vol. 2, 2nd ed. New York: Marcel Decker; 1990
   Google Scholar
• Mishra A, Kapoor A, Bhargava S. Proniosoml gel as a carrier for improved transdermal drug delivery. Asian J Pharm Life Sci 2011;1:370–379
   Google Scholar
• Gayatri DS, Venkatesh P, Udupa N. Niosomal sumatriptan succinate for nasal administration. Int J Pharm Sci 2000;62:479–481
   Google Scholar
• Vyas SP, Khar RK. Targeted and controlled drug delivery: novel carrier systems. New Delhi: CBS Publications; 2002
   Google Scholar
• Chauhan S, Luorence MJ. The preparation of polyoxyethylene containing non-ionic surfactant vesicles. J Pharm Pharmacol 1989;41:6–11
   Google Scholar
• Ajay S, Jolly P, Rajesh P. Preparation, characterization, optimization, and stability studies of Aceclofenac Proniosomes. Iran J Pharm Res 2008;7:237–246
   Web of Science ®Google Scholar
• Office of Training and Communication, Division of Drug Information, HFD-240, Center for Drug Evaluation and Research, FDA. November 2003. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073369.pdf
   Google Scholar
• Martin A, Swarbrick J. Cammarata A.Physical Pharmacy (3rd ed.). Philadelphia (USA): Lea and Febiger; 1993
   Google Scholar
• Hao Y, Zhao F, Li N, et al. Studies on a high encapsulation of colchicine by a niosome system. Int J Pharm 2002;244:73–80
   PubMed Web of Science ®Google Scholar
• Azarbayjani AF, Tan EH, Chan YW, et al. Transdermal delivery of haloperidol by proniosomal formulations with non-ionic surfactants. Biol Pharm Bull 2009;32:1453–1458
   PubMed Web of Science ®Google Scholar
• Sankar V, Praveen C, Prasanth KG, et al. Formulation and evaluation of a proniosome hydrocortisone gel in comparison with a commercial cream. Pharmazie 2009;64:731–734
   PubMed Web of Science ®Google Scholar
• Azeem A, Ahmad FJ, Talegaonkar S. Exploration of skin permeation mechanism of frusemide with proniosomes. Pharmazie 2009;64:735–740
   PubMed Web of Science ®Google Scholar
• Wen MM, Farid RM, Kassem AA. Nano-proniosomes enhancing the transdermal delivery of mefenamic acid. J Liposome Res 2014;24:280–289
   PubMed Web of Science ®Google Scholar
• Ramkanth S, Chetty CM, Sudhakar Y. Development and in vitro permeation studies of proniosomal based transdermal delivery system of Atenolol. Pak J Pharm Sci 2014;27:115–120
   PubMed Web of Science ®Google Scholar
• Imam SS, Aqil M, Akhtar M, et al. Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv 2015;22:1059–1070
   PubMed Web of Science ®Google Scholar
• Prasad PS, Imam SS, Aqil M, et al. QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. Drug Deliv 2015. [Epub ahead of print]. DOI: 10.3109/10717544.2014.936536
   PubMed Web of Science ®Google Scholar
• Ahmed S, El-Setouhy DA, El-Latif Badawi AA, El-Nabarawi MA. Provesicular granisetron hydrochloride buccal formulations: in vitro evaluation and preliminary investigation of in vivo performance. Eur J Pharm Sci 2014;60:10–23
   PubMed Web of Science ®Google Scholar
• Sahoo RK, Biswas N, Guha A, et al. Maltodextrin based proniosomes of nateglinide: bioavailability assessment. Int J Biol Macromol 2014;69:430–434
   PubMed Web of Science ®Google Scholar
• Akhtar M, Imam SS, Afroz Ahmad M, et al. Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: in vitro and ex vivo study. Drug Deliv 2014;21:487–494
   PubMed Web of Science ®Google Scholar
• Nasr M. In vitro and in vivo evaluation of proniosomes containing celecoxib for oral administration. AAPS PharmSciTech. 2010;11:85–89
   PubMed Web of Science ®Google Scholar
• Najlah M, Hidayat K, Omer HK, et al. A facile approach to manufacturing non-ionic surfactant nanodipsersions using proniosome technology and high-pressure homogenization. J Liposome Res 2015;25:32–37
   PubMed Web of Science ®Google Scholar
• Li Q, Li Z, Zeng W, et al. Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci 2014;62:115–123
   PubMed Web of Science ®Google Scholar
• Alam MI, Baboota S, Kohli K, et al. Pharmacodynamic evaluation of proniosomal transdermal therapeutic gel containing celecoxib. Science Asia 2010;36:305–311
   Web of Science ®Google Scholar
• Prajapati SK, Kumar S, Sahu VK, et al. Proniosomal gel of flurbiprofen: formulation and evaluation. J Drug Deliv Ther 2012;2:1–5
   Google Scholar
• Goyal C, Ahuja M, Sharma SK. Preparation and evaluation of anti-inflammatory activity of gugulipid-loaded proniosomal gel. Acta Pol Pharm 2011;68:147–150
   PubMed Web of Science ®Google Scholar
• Patil HN, Sharwareer H, Ashok V. Formulation development & evaluation of proniosomal gel of Carvedilol. Int J Pharm Pharm Sci 2011;4:191–197
   Google Scholar
• Ammar HO, Ghorab M, El-Nahhas SA, et al. Proniosomes as a carrier system for transdermal delivery of tenoxicam. Int J Pharm 2011;405:142–152
   PubMed Web of Science ®Google Scholar
• Abdelbary GA, Aburahma MH. Oro-dental mucoadhesive proniosomal gel formulation loaded with lornoxicam for management of dental pain. J Liposome Res 2014;25:107–121
   PubMed Web of Science ®Google Scholar
• Ibrahim MM, Shehata TM. The enhancement of transdermal permeability of water soluble drug by niosome-emulgel combination. J Drug Deliv Sci Tech 2012;22:353–359
   Web of Science ®Google Scholar
• Gurrapu A, Jukanti R, Bobbala SR, et al. Improved oral delivery of valsartan from maltodextrin based proniosome powders. Adv Powder Technol 2012;23:583–590
   Web of Science ®Google Scholar
• Parthibarajan R, Rubinareichal C, Loganathan S. Formulation and evaluation of methotrexate proniosomal powder. Int J Pharm Pharm Sci 2012;4:175–178
   Google Scholar